… Current pharmacological therapy available for conditions presenting with dementia, such
as Alzheimer's disease and Parkinson's disease, is primarily symptomatic with minimal side …

Parkinson’s disease (PD), the second most common age-related neurodegenerative
disease, results from the loss of dopamine neurons in the substantia nigra. This disease is …

… Leptin and associates mediators regulate neuroinflammation in Parkinson‘s disease As
outlined above (section 3), there are strong emerging links between the progression of PD and …

… to OFF periods, including emerging strategies. Unmet clinical needs will be discussed,
including non-motor symptoms, targeted molecular therapies and disease modifying therapy. …

… Recently, a multimodal biomarker battery in PD has emerged and might play an important …
NMS Scale, as well as the IPMDS unified Parkinson's disease rating scale (UPDRS) part 1. In …

… The list of encapsulated drugs and the nature of the particles … of the latest advances and
emerging frontiers in micro- and … to administer therapeutic agents in Parkinson's disease. …

… In this review we will focus on the mitochondria-related cellular derangements in Parkinson's
disease, in which genetic models have permitted to identify common patterns that share a …

Ionotropic glutamate receptors (iGluRs) mediate the majority of excitatory neurotransmission
and are implicated in various neurological disorders. In this review, we discuss the role of …

Parkinson’s disease (PD) is a neurodegenerative disease due to the degeneration of
dopaminergic neurons (DNs) in the substantia nigra (SN). The liver X receptor (LXR) is involved in …

… Therefore, the development of novel iron chelators as neuroprotective agents for the
treatment of neurodegeneration is an emerging trend. Several iron chelators including 8-…